Books > Medicine > Nursing & ancillary services > Specific disorders & therapies
|
Not currently available
Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases (Hardcover, 1st ed. 2017)
Loot Price: R4,118
Discovery Miles 41 180
You Save: R277
(6%)
|
|
Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases (Hardcover, 1st ed. 2017)
Series: Progress in Inflammation Research
Supplier out of stock. If you add this item to your wish list we will let you know when it becomes available.
|
As our understanding of immune mediated chronic inflammatory
diseases (IMIDs) grows, it becomes more and more clear that these
conditions result from the convergence of a multitude of pathogenic
mechanisms whose relative individual contribution is different in
different patient subsets. Promising new technologies have been
conceived that address the hypotheses that targeting multiple
pathways simultaneously, selectively delivering therapeutics to
areas of inflammation and/or resetting the immune system, could
take efficacy to new levels. However, we have long waited for the
arrival of some of these technologies to the bedside, or even far
enough in the drug development process in spite of the initial
enthusiasm. Some of the examples covered in this book include
bispecific antibodies and genomic medicines, microparticles and
targeted delivery of drugs to inflamed vasculature. Most published
reviews and book chapters on novel therapies for inflammatory
diseases describe positive attributes of molecules or technologies
under investigation and the rationale for developing them into
therapeutics. The originality and potential value of this book is
not in the description of these targets or technologies from the
point of view of their structure or mechanism of action
exclusively, but rather, in making an effort to critically address
the question of what is needed to move these technologies into the
clinic. Has the technology not made it past the preclinical stage
and why? Has it already been tested in humans and failed? What are
the potential reasons behind those failures? What do experts in
each field believe can be done better to increase the probabilities
of success? In addition, the authors address the competitive
landscape and summarize clinical studies that have failed in the
respective area. They talk about the patient populations that would
be required for the successful conduction of a clinical trial to
test certain molecules, and they proactively share their views
regarding both the potential and the drawbacks of targets or
methodologies.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.